AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26185423
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) formulation of cilostazol 200 mg every 24 hours
Trial: 26185423
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) formulation of cilostazol 100 mg every 12 hours
Trial: 23448818
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of rabbit antithymocyte globulin
Trial: 21063786
Drug: Acute migraine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute migraine treatment
Trial: 26772449
Drug: Combined vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vitamin A-zinc supplement
Trial: 9306340
Drug: Intensified antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified antihypertensive treatment (felodipine, metoprolol, or ramipril)
Trial: 8374373
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and non-steroidal anti-inflammatory drugs
Trial: 8374373
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs prescribed for longer than five years
Trial: 8374373
Drug: Paracetamol or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol or other drugs
Trial: 26195963
Drug: Duloxetine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine therapy with pelvic floor exercise (Group A)
Trial: 18307594
Drug: Lamivudine (LAM;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (LAM; 100 mg, q.d.)
Trial: 18307594
Drug: Interferon +
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon + Lamivudine combination (2 months of LAM followed by combination treatment)
Trial: 14762857
Drug: Interferon monotherapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon monotherapy
Trial: 16451437
Drug: School-based caries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based caries preventive program including intensive oral hygiene instructions and supervised daily tooth brushing with fluoridated toothpaste.
Trial: 16451437
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only oral hygiene instructions sessions.
Trial: 12954659
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in eugonadal men
Trial: 6805647
Drug: Adrenergic-blocking agents
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic-blocking agents (propranolol and phentolamine or propranolol alone) for three weeks
Trial: 30924762
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy (EVT with IVT)
Trial: 11940752
Drug: Colforsin daropate
RxNorm normalized name: Tropine tropate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colforsin daropate (0.75 microg x kg(‐1) x min(‐1) continuous infusion for 60 min)
Trial: 11940752
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (7.5 mL/hr continuous infusion)
Trial: 9806696
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral dextromethorphan
Trial: 8529331
Drug: Fosinopril (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (intravenous and oral)
Trial: 8529331
Drug: Fosinopril (oral)
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosinopril (oral)
Trial: 2131458
Drug: Chewable tablets
RxNorm normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablets containing pyridoxine and heat‐killed lactic bacteria
Trial: 2132274
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets with pyridoxine only
Trial: 7115241
Drug: Autogenic-feedback training
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenic-feedback training (AFT) for highly susceptible subjects (Treatment Group I)
Trial: 7115241
Drug: Autogenic-feedback training
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenic-feedback training (AFT) for moderately susceptible subjects (Treatment Group II)
Trial: 31420787
Drug: PL‐ASA 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL‐ASA 325 mg
Trial: 31420787
Drug: PL‐ASA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL‐ASA 650 mg
Trial: 31420787
Drug: IR‐ASA 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐ASA 325 mg
Trial: 31420787
Drug: IR‐ASA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐ASA 650 mg
Trial: 25826678
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid administration (S-group)
Trial: 25826678
Drug: Reduced fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced fluid administration (R-group)
Trial: 24890250
Drug: Structured preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured preparation meeting and access to population-based data
Trial: 21789881
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily oral DHEA for 28 days
Trial: 11815423
Drug: Short-term estrogen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term estrogen administration (25 mg of conjugated equine estrogens IV)
Trial: 11815423
Drug: Long-term hormone
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term hormone replacement therapy (HRT)
Trial: 10412515
Drug: rh-GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-GH therapy (0.250 IU/Kg/week)
Trial: 10412515
Drug: rh-GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-GH therapy
Trial: 7748051
Drug: Nondihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondihydropyridine calcium antagonists
Trial: 7748051
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium antagonists
Trial: 28776117
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (0.25 mg/12 h) administered the day before hCG trigger
Trial: 28776117
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no double dose of GnRH antagonist)
Trial: 19154566
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin supplementation (0.8 mg folic acid, 0.5 mg cyanocobalamin, and 3 mg pyridoxine daily for 6 months)
Trial: 26386802
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unfractionated heparin
Trial: 11150025
Drug: low‐molecular‐weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐molecular‐weight heparin
Trial: 9456420
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam (1 mg)
Trial: 7653747
Drug: 0.125% cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% cetirizine nasal spray
Trial: 7653747
Drug: 0.06% cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% cetirizine nasal spray
Trial: 7653747
Drug: 0.25% cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% cetirizine nasal spray
Trial: 3670682
Drug: Thymomodulin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymomodulin (120 mg/die for 20 days/month for 4 months)
Trial: 3670682
Drug: Thymomodulin in
RxNorm normalized name: thymomodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymomodulin in association with vaccine (120 mg/die for 20 days/month for 4 months)
Trial: 3670682
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of vaccine-thymomodulin
Trial: 31128008
Drug: Preoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative infusion chemotherapy combined with hyperthermia
Trial: 12780755
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg/m2)
Trial: 12780755
Drug: Dexamethasone (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (6.5 mg/m2)
Trial: 11214010
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment for acute myocardial infarction in left bundle branch block
Trial: 11214010
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment for acute myocardial infarction in right bundle branch block
Trial: 8939767
Drug: 1 of
RxNorm normalized name: lisocabtagene maraleucel, CD8 component, 1 of 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 2 doses of vitamin D+Ca
Trial: 3976636
Drug: Both metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both metoclopramide doses
Trial: 31258019
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, anemic mothers)
Trial: 31258019
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, non-anemic mothers)
Trial: 31258019
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, anemic and non-anemic mothers)
Trial: 25872790
Drug: Colistin 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin 4.5 MU as a loading dose, followed by 3 MU every eight hours, combined with levofloxacin
Trial: 25872790
Drug: Meropenem 2
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2 g every eight hours, combined with levofloxacin
Trial: 24225149
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care + smartphone application (Glucose Buddy) with weekly text-message feedback from a Certified Diabetes Educator
Trial: 11176979
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost for 3 months (n = 8)
Trial: 11176979
Drug: Alternative medication
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative medication for 3 months (n = 9)
Trial: 7941592
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no KLH treatment)
Trial: 18457786
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (FCs with monthly contact from Healthy Eating Coordinator)
Trial: 18457786
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (FCs without monthly contact from Healthy Eating Coordinator)
Trial: 12635790
Drug: Resorbable Shuttle
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resorbable Shuttle Stop (HC Implants, BV. Leiden, The Netherlands)
Trial: 9298778
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g daily for 5 days)
Trial: 8509527
Drug: ECT twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT twice a week
Trial: 25772212
Drug: MamaNatalie (MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MamaNatalie (MG) - 45 minutes of SVD simulation using an obstetrical abdominal-pelvic model
Trial: 18410326
Drug: Oral extended-release
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release oxybutynin 5 mg once daily
Trial: 16368813
Drug: Frakefamide (FF)
RxNorm normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frakefamide (FF) 1.22 mg/kg
Trial: 16368813
Drug: Morphine (M-large)
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (M-large) 0.44 mg/kg
Trial: 16368813
Drug: Placebo (Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Sodium chloride 9 mg/mL)
Trial: 8975955
Drug: Fiber supplement
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplement (Plantago Ovata)
Trial: 20690893
Drug: Oxybutynin immediate-release
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin immediate-release 15 mg/day
Trial: 15948985
Drug: Pimecrolimus 10
RxNorm normalized name: pimecrolimus 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 10 mg b.d.
Trial: 15948985
Drug: Pimecrolimus 20
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 20 mg b.d.
Trial: 15948985
Drug: Pimecrolimus 30
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 30 mg b.d.
Trial: 12563622
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (94 mg Ox + 26 mg Ca)
Trial: 12563622
Drug: Milk chocolate
RxNorm normalized name: Meritene Milk Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk chocolate (94 mg Ox + 430 mg Ca)
Trial: 1846787
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 6, 35, 200 or 1200 m-units min-1 m-2 for 2 hours
Trial: 1846787
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at higher rates
Trial: 29500678
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message support (daily text message for 1 year)
Trial: 8583793
Drug: TCV-116 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-116 2.5 mg
Trial: 8583793
Drug: TCV-116 5
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-116 5 mg
Trial: 6277642
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 (5 mg i.m.)
Trial: 6277642
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 (20 mg i.m.)
Trial: 6277642
Drug: Alcohol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.5 g/kg)
Trial: 21345942
Drug: Candesartan (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (32 mg/day)
Trial: 11740193
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg once daily for the first 2 weeks)
Trial: 9922474
Drug: Pamidronate infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate infusions (30 or 45 mg weekly)
Trial: 9922474
Drug: Pamidronate infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate infusions (30 or 45 mg every three months or 90 mg every six months)
Trial: 8118635
Drug: Bronchodilator (BD)
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (BD) treatment
Trial: 4890207
Drug: Azathioprine-prednisolone combination
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine-prednisolone combination
Trial: 4890207
Drug: Azathioprine-prednisolone treatment
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine-prednisolone treatment prolonged to one year
Trial: 28371937
Drug: Naldemedine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.1 mg
Trial: 28371937
Drug: Naldemedine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.4 mg
Trial: 9625095
Drug: Luteolin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteolin (279 micromol/L)
Trial: 9625095
Drug: Myricetin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myricetin (279 micromol/L)
Trial: 9625095
Drug: Quercetin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (279 micromol/L)
Trial: 9625095
Drug: Kaempferol (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferol (279 micromol/L)
Trial: 9625095
Drug: Quercitrin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercitrin (279 micromol/L)
Trial: 9625095
Drug: Apigenin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apigenin (279 micromol/L)
Trial: 9625095
Drug: Quercetin-3-glucoside (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin-3-glucoside (279 micromol/L)
Trial: 9625095
Drug: Rutin (279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutin (279 micromol/L)
Trial: 9625095
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (279 micromol/L)
Trial: 9625095
Drug: Quercetin (23.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (23.2 micromol/L)
Trial: 9625095
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (23.2 micromol/L)
Trial: 9625095
Drug: Quercetin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin and Vitamin C (23.2 micromol/L each)
Trial: 3375957
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for lung cancer in asbestos-exposed patients
Trial: 30388439
Drug: Spermidine-rich plant
RxNorm normalized name: spermidine
DrugBank: Spermidine (DB03566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermidine-rich plant extract supplement
Trial: 27342073
Drug: Combined Training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Training (HIIT + RT): Combination of both HIIT and RT interventions.
Trial: 24941837
Drug: Integrated Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Chinese medical treatment (CM treatment) as maintenance therapy
Trial: 24941837
Drug: Western drug
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western drug chemotherapy (Gemcitabine or Alimta or docetaxel)
Trial: 22619193
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 4 mg/mL dexamethasone sodium phosphate
Trial: 22619193
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of normal saline (placebo)
Trial: 20927003
Drug: Constraint Induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint Induced Movement Therapy
Trial: 16085220
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a soluble TNF receptor (TNFR:Fc, etanercept, Enbrel) 25mg subcutaneously, twice weekly for 2 weeks
Trial: 11918622
Drug: Atorvastatin (hydroxymethylglutaryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (hydroxymethylglutaryl coenzyme A reductase inhibitor)
Trial: 10400847
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 25 microgram once daily